BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29207175)

  • 1. Hypermethylation of the SPARC promoter and its prognostic value for prostate cancer.
    Liu T; Qiu X; Zhao X; Yang R; Lian H; Qu F; Li X; Guo H
    Oncol Rep; 2018 Feb; 39(2):659-666. PubMed ID: 29207175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers.
    Yang E; Kang HJ; Koh KH; Rhee H; Kim NK; Kim H
    Int J Cancer; 2007 Aug; 121(3):567-75. PubMed ID: 17397030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant promoter methylation of SPARC in ovarian cancer.
    Socha MJ; Said N; Dai Y; Kwong J; Ramalingam P; Trieu V; Desai N; Mok SC; Motamed K
    Neoplasia; 2009 Feb; 11(2):126-35. PubMed ID: 19177197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone.
    Sharma S; Xing F; Liu Y; Wu K; Said N; Pochampally R; Shiozawa Y; Lin HK; Balaji KC; Watabe K
    J Biol Chem; 2016 Sep; 291(37):19351-63. PubMed ID: 27422817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
    Cheetham S; Tang MJ; Mesak F; Kennecke H; Owen D; Tai IT
    Br J Cancer; 2008 Jun; 98(11):1810-9. PubMed ID: 18458674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of the SPARC gene promoter and its clinical implication in gastric cancer.
    Chen ZY; Zhang JL; Yao HX; Wang PY; Zhu J; Wang W; Wang X; Wan YL; Chen SW; Chen GW; Liu YC
    Sci Rep; 2014 Dec; 4():7035. PubMed ID: 25516351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation of SPARC in human lung cancers.
    Suzuki M; Hao C; Takahashi T; Shigematsu H; Shivapurkar N; Sathyanarayana UG; Iizasa T; Fujisawa T; Hiroshima K; Gazdar AF
    Br J Cancer; 2005 Mar; 92(5):942-8. PubMed ID: 15756262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model.
    Ribeiro N; Costa-Pinheiro P; Henrique R; Gomez-Lazaro M; Pereira MP; Mansur AAP; Mansur HS; Jerónimo C; Sousa SR; Monteiro FJ
    J Biomed Nanotechnol; 2016 Aug; 12(8):1667-78. PubMed ID: 29342345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma.
    Rodríguez-Jiménez FJ; Caldés T; Iniesta P; Vidart JA; Garcia-Asenjo JL; Benito M
    Oncol Rep; 2007 Jun; 17(6):1301-7. PubMed ID: 17487382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Prognostic Role of
    Fabrizio FP; Sparaneo A; Fontana A; Mazza T; Graziano P; Pantalone A; Parente P; Centra F; Orlando N; Trombetta D; Torre A; Ferretti GM; Taurchini M; Micco CMD; Maiello E; Fazio VM; Rossi A; Muscarella LA
    Cells; 2020 Jun; 9(6):. PubMed ID: 32580473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
    Li Y; Meng L; Shi T; Ren J; Deng Q
    Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved response to nab-paclitaxel compared with cremophor-solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non-small cell lung cancer.
    Shao H; Tang H; Salavaggione OE; Yu C; Hylander B; Tan W; Repasky E; Adjei AA; Dy GK
    J Thorac Oncol; 2011 Jun; 6(6):998-1005. PubMed ID: 21532503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant methylation of secreted protein acidic and rich in cysteine gene and its significance in gastric cancer.
    Shao S; Zhou NM; Dai DQ
    World J Gastroenterol; 2019 Dec; 25(46):6713-6727. PubMed ID: 31857774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ssDNA-binding protein 2 is frequently hypermethylated and suppresses cell growth in human prostate cancer.
    Liu JW; Nagpal JK; Sun W; Lee J; Kim MS; Ostrow KL; Zhou S; Jeronimo C; Henrique R; Van Criekinge W; Moon CS; Califano JA; Trink B; Sidransky D
    Clin Cancer Res; 2008 Jun; 14(12):3754-60. PubMed ID: 18559593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.
    Gao J; Song J; Huang H; Li Z; Du Y; Cao J; Li M; Lv S; Lin H; Gong Y
    J Exp Clin Cancer Res; 2010 Mar; 29(1):28. PubMed ID: 20338068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.